Related Topics

LinkedIn
Vimeo
Facebook

Press

Genea Gets Orphan Drug Designation

Genea Biocells Announces FDA Orphan Drug Designation for GBC0905 For The Treatment Of  Facioscapulohumeral Muscular Dystrophy (FSHD) San Diego (CA), May 30, 2018 -- Genea Biocells, a preclinical-stage company focused on...

Read More

Genea Biocells partners with AMSBIO

Genea Biocells (San Diego, USA) has partnered with AMSBIO for global distribution to the academic community for its leading-edge skeletal muscle differentiation kits.   For more information please visit:  AMSBIO and Genea Biocells...

Read More

Stem Cells Bring Hope for Dystrophies

Genea Biocells, a world leader in skeletal muscle differentiation also possesses one of the world’s largest and most varied private human embryonic stem cell banks–giving us the ability to recapitulate...

Read More